Volume 2006, Issue 2
  • ISSN: 0253-8253
  • EISSN: 2227-0426


Metabolic syndrome, the association of obesity, hypertension and hyperlipidaemia in conjunction with impaired glucose tolerance or frank diabetes, is a rising global pattern and has been subjected to a useful consensus re-definition in recent months. Its origins are fixed in changing dietary and activity patterns across the developed world but also increasingly affecting all developing economies. The obvious sequelae of this spiraling pattern are increases of atherosclerotic vascular disease and subsequent occlusive vascular events, morbidity and premature mortality for affected patients. Given its emerging importance we should consider carefully the role of the sympathetic nervous system in the overlapping management of the pathophysiology of obesity and hypertensive vascular disease; the recognition of the metabolic syndrome and its definition in practice; and whether new trial results pertinent to managing hypertension in the overweight patient with metabolic syndrome using the central imidazoline antagonist drug, moxonidine, might prompt reconsideration of this established strategy for lowering blood pressure.


Article metrics loading...

Loading full text...

Full text loading...


  1. Alberti KGMM, Zimmett P, Shaw J. for the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome a new worldwide definition. Lancet. 2005; 366::10591061.
    [Google Scholar]
  2. Grassi G. Debating sympathetic overactivity as a hallmark of human obesity: A pro's position. J Hypertension. 1999; 17::10591060.
    [Google Scholar]
  3. Zebekakis PE, Naw rot T, Balke stein EJ, Van den Heijden-Spek J, Van Bortel LM, Struijker-Boudier HA, Staessen JA. Obesity is associated with increased arterial stiffness from adolescence until old age. J. Hypertension. 2005; 23::18391846.
    [Google Scholar]
  4. Grassi G, DelVOro R, Facchini A, Trevano FQ, Bolla GB, Mancia G. Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives. J. Hypertension. 2004; 22::23632369.
    [Google Scholar]
  5. Reaven G. Role of insulin resistance in human disease Diabetes. 1988; 37::15951607.
    [Google Scholar]
  6. Yusuf S, Hawken S, Oupuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L. on behalf of the INTERHEART Investigators Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the Interheart study): Case control study. Lancet. 2004; 364::937952.
    [Google Scholar]
  7. Giles TD, Sander GE. Pathophysiologic, diagnostic, and therapeutic aspects of the metabolic syndrome. J Clin Hypertens. 2005; 7:11:669678.
    [Google Scholar]
  8. Morris STW, Reid JL. Moxonidine a review. J. Human Hypertension. 1997; 11::629635.
    [Google Scholar]
  9. Olsen MH, Fossum E, Hoieggen A, Wachtell K, Hjerkinn E, Nesbitt SD, Andersen UB, Phillips RA, Gaboury CL, Ibsen H, Kjeldsen SE, Julius S. Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. J Hypertension Apr. 2005; 23:4:891898.
    [Google Scholar]
  10. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, Mclnnes GT, Mehlsen J, Nieminen M, O 'Brien E, Ostergren J. ASCOT Investigators Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA): a multicentre randomised controlled trial. Lancet. 2005; 366:9489:895906, Sep 10-16.
    [Google Scholar]
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error